The apoC3 inhibitor, Tryngolza (olezarsen), has been approved by the US Food and Drug Administration (FDA) for use in adults with familial chylomicronaemia syndrome (FCS) as an adjunct to diet.
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
